Key Highlights

• Twin Target Hikes: BofA Securities lifted its target to $36 from $25 (Neutral), while Canaccord Genuity raised its Buy-rated target to $40 from $32.

• Landmark GLP-1 Partnerships: Deals with Novo Nordisk and Eli Lilly expanded the branded drug lineup and cleared key regulatory and legal overhangs.

• Outperforming the Market: Shares are sharply beating a flat XLV and a modestly higher S&P 500 on the first trading day of H2 2026.

Hims & Hers Health, Inc. (NYSE: HIMS) is riding a wave of fresh analyst optimism, with two firms lifting their price targets in quick succession. BofA Securities raised its target to $36 from $25 while maintaining a Neutral rating, and Canaccord Genuity increased its Buy-rated target to $40 from $32.

The upgrades cap an eventful stretch for the telehealth company. Hims & Hers (NYSE: HIMS) struck landmark GLP-1 partnerships with both Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY), a pair of deals that expanded its branded drug lineup and, importantly, removed regulatory and legal overhangs that had clouded the stock.

Those partnerships matter for more than product selection. GLP-1 weight-loss treatments have become one of the most powerful growth engines in healthcare, and securing branded supply through the two dominant manufacturers gives Hims & Hers a firmer footing in a category where compounded alternatives have faced mounting scrutiny.

That scrutiny surfaced again overnight. FDA scientists raised safety questions about seven popular peptides, a development that could weigh on companies leaning on compounded formulations. At least one analyst characterized the news as 'not the end' for the company's compounding ambitions, framing it as a manageable headwind rather than a structural threat.

The market reaction underscores the bullish tone. Shares are sharply outperforming the broader healthcare sector, with the XLV exchange-traded fund trading essentially flat, and the S&P 500 posting only a modest gain on the first trading day of the second half of 2026.

The divergence between Hims & Hers and its sector peers reflects a company-specific catalyst set rather than a broad sector move. Analyst target hikes, cleared overhangs, and expanded branded access have combined to shift sentiment, even as the peptide question lingers in the background.

For investors, the setup presents a familiar tension. The bull case rests on the GLP-1 partnerships, a growing subscriber base, and a clearer regulatory path. The bear case, or at least the cautious case reflected in BofA's Neutral rating, points to valuation, the durability of the compounding business, and the risk that peptide safety questions escalate.

The spread between the two new targets, $36 versus $40, itself illustrates the debate. Both moved higher, but the ratings diverge, with one firm seeing fair value and the other seeing further upside.

The key items to watch for Hims & Hers (NYSE: HIMS) include the rollout of its branded GLP-1 offerings, any follow-up from the FDA on the flagged peptides, and subscriber and revenue trends in upcoming quarters. For now, the analyst community has clearly warmed to the story, and the stock's outperformance reflects that shift. This article is for informational purposes only and is not investment advice.

()